DEA Bans Five Weird Hallucinogens: Tryptamine Trip Ends
Published Date: 9/23/2026
Proposed Rule
Summary
The Drug Enforcement Administration wants to put five specific hallucinogenic drugs into Schedule I, meaning they’ll be treated as illegal with strict rules. This affects anyone who makes, sells, studies, or owns these drugs, adding serious legal consequences. You have until October 23, 2026, to share your thoughts or ask for a hearing before the rule might become official.
Analyzed Economic Effects
6 provisions identified: 0 benefits, 5 costs, 1 mixed.
Five tryptamines moved to Schedule I
The Drug Enforcement Administration proposes to place 4-OH-DiPT, 5-MeO-AMT, 5-MeO-MiPT, 5-MeO-DET, and DiPT into Schedule I. If finalized, these substances would be treated as illegal under the Controlled Substances Act and subject to the civil, administrative, and criminal sanctions that apply to Schedule I drugs.
Retail sales banned; unauthorized possession illegal
The Controlled Substances Act does not allow retail sales of Schedule I drugs to the general public. Possession of any quantity of these substances without authorization under the CSA would be unlawful and could lead to prosecution.
DEA registration required to handle substances
Anyone who manufactures, distributes, imports, exports, researches, analyzes, or possesses these five tryptamines would need to be registered with DEA under the Controlled Substances Act. The rule says people currently handling them who are not registered must apply for registration and may not continue handling them unless DEA approves the application.
90-day rule to continue some research after scheduling
If the final rule is effectuated, a person already registered to conduct research with another Schedule I controlled substance may continue research on these five tryptamines only if they submit a completed application or modification to conduct research with them within 90 calendar days after the date the final rule takes effect. The person may continue research until they withdraw the application or the Administrator serves an order to show cause; if an order to show cause is served, a requested hearing must be held on an expedited basis not later than 45 calendar days after the request, unless the person agrees to a later date.
Surrender or transfer stock before effective date
People who are unwilling or unable to obtain a Schedule I registration must surrender or transfer all quantities of these substances to a DEA-registered person before the effective date of the final scheduling action, and dispose of them according to applicable law and 21 CFR part 1317. That means labs or suppliers holding stocks must either register or move/securely dispose of their inventories before the rule takes effect.
Schedule I security and storage rules apply
If these tryptamines are placed in Schedule I, they would be subject to Schedule I security requirements and must be handled and stored in accordance with the Controlled Substances Act and implementing regulations. That will require entities that keep these substances to meet Schedule I physical security and recordkeeping rules.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20749, Vladimir Romaniv, P.A.; Decision and Order
The DEA has officially suspended and is moving to revoke Vladimir Romaniv, P.A.'s registration because he gave multiple prescriptions without properly checking on a patient who was in jail. This affects Romaniv’s ability to prescribe controlled substances and signals serious legal trouble starting from late 2025. If you’re connected to his practice or rely on his prescriptions, expect changes and tighter controls soon.
2026-20750, L Krenk DBA Maui Clinic Pharmacy; Decision and Order
The DEA has officially revoked L Krenk DBA Maui Clinic Pharmacy’s registration because they broke important rules about where and how they handled controlled substances. This affects the pharmacy in Kahului, Hawaii, which can no longer legally dispense these drugs. The decision is final, and the pharmacy missed its chance to defend itself, so the revocation takes effect immediately, impacting their business and customers.
Previous / Next Documents
Previous: 2026-19370, Part 572; Anthropomorphic Test Devices; Test Device for Human Occupant Restraint 50th Percentile Adult Male Dummy (THOR-50M)
NHTSA is updating crash test rules to include a smarter crash test dummy called the THOR-50M, which better represents an average adult male. They’re asking for feedback on new spine designs and face foam options to make tests more accurate. If you’re involved in car safety or testing, get your comments in by October 22, 2026—this could shape future safety rules and testing costs.
Next: 2026-19411, Airworthiness Directives; Textron Aviation, Inc. (Type Certificate Previously Held by Cessna Aircraft Company) Airplanes
If you own or fly certain Textron (formerly Cessna) Model 402C and 414A airplanes, the FAA wants you to check your engine beams more often for cracks and replace them once they hit a new life limit. This keeps your plane safe and sound, but it means some extra inspections and possible replacements soon. Comments on this plan are open until November 9, 2026, so speak up if you have thoughts!